Navigation Links
Critical Pharmaceuticals Enter Sustained Release hGH Arena

Preclinical Results of New Somatropin Formulation Demonstrate Advantages

Over Existing Once-Daily Product

NOTTINGHAM, England, October 1 /PRNewswire/ -- Critical Pharmaceuticals, the Nottingham, UK-based speciality pharmaceuticals company, today announced that the successful completion of preclinical trials of a sustained release formulation of the synthetic human growth hormone (hGH) somatropin. Trials demonstrated therapeutic plasma concentrations were achieved over an extended period of time supporting the development of the product as a once every two weekly injection. In addition, the efficacy profile using biomarkers was comparable to current daily formulations.

The new formulation was produced using Critical's patented CriticalMix delivery technology, which is based on world leading supercritical fluid expertise. This enables the optimal encapsulation of drugs into injectable microparticles with superior drug release properties. hGH delivery is a natural application for this technology, and the company now intends to take this product forward into Phase 1 clinical trials. This decision coincides with a recent report by Frost & Sullivan valuing the European market at $846.4m in 2007, with a compound annual growth rate (CAGR) of 2.4 per cent from 2007 to 2014. The report also highlighted new delivery methods together with approval for new indications as keys to success.

According to Chief Business Officer Gareth King, these preclinical results mark an important milestone for the company: "Over the past few years, we have concentrated on optimizing our delivery technologies and ensuring they are transferable from the lab into an industrial setting. Sustained release hGH is one of three projects we are now developing in areas of unmet need. There is no doubt that a sustained release version of hGH would be preferred by patients, particularly paediatric, but there are naturally concerns over safety and efficacy. We are confident the highly controlled release rates achieved with our technology will overcome these concerns. The plan is now to take this product into clinic either by ourselves or in partnership. We are also in preclinical development with sustained release Risperidone and, demonstrating the versatility of our technology platform, a once-daily nasal formulation of hGH."

About Critical Pharmaceuticals

Critical Pharmaceuticals is a Nottingham UK-based biotechnology company with proprietary drug delivery technologies for the sustained release and nasal delivery of proteins and peptides and labile or insoluble small molecules. Critical Pharmaceuticals was founded by Professor Steve Howdle in 2002 based on his world leading research into supercritical fluids. Professor Howdle noticed that supercritical carbon dioxide was able to liquify certain polymers, and in a moment of inspiration realised that this could be used to encapsulate thermally labile or solvent sensitive drugs to create injectable sustained release products. As well as working in partnership with other pharmaceutical and biotechnology companies, the company is now developing a pipeline of reformulated drug candidates for areas of unmet needs including human growth hormone. For more information visit

Corporate Inquiries

Gareth King, Chief Business Officer

Critical Pharmaceuticals,

BioCity Nottingham NG1 1GF UK

Tel +44-115-8820100; +44-7720-051988


SOURCE Critical Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill
2. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
3. REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
4. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
5. Microlifes Home Blood Pressure Monitors Proven Accurate Even for Critical Patients
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
11. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):